



The New Impact Factor of International Brazilian Journal of Urology Is 4.3

Luciano A. Favorito ^{1, 2}

¹ Unidade de Pesquisa Urogenital - Universidade do Estado do Rio de Janeiro - Uerj, Rio de Janeiro, RJ, Brasil; ² Serviço de Urologia, Hospital Federal da Lagoa, Rio de Janeiro, RJ, Brasil

In June 2026 Clarivate released the impact factor of 2026 (Figure-1). To our great satisfaction, The International Brazilian Journal of Urology achieved an impact factor of 4.3 (the cover in this edition). With this impact factor, The International Brazilian Journal of Urology establishes itself as one of the ten most important in the field of urology: a feat that would have been unthinkable in the past. In the present evaluation The International Brazilian Journal of Urology maintained your category ranking (Figure-2). This achievement was made possible only thanks to the Board of the Brazilian Society of Urology, the tireless work of the associate editors, and the prompt availability of the reviewers. Our journal is fully open-access—a unique service made possible by the pioneering spirit of the Brazilian Society of Urology. The Editor-in-Chief extends sincere thanks to everyone involved, especially the technical editorial team, who do outstanding work. We will discuss some articles from this edition below.

Figure 1 - Impact factor of Int Braz J Urol in present year.

$$\frac{\text{Citations in 2025 to items published in 2023 (253) - 2024 (224)}}{\text{Number of citable items in 2023 (54) + 2024 (56)}} = \frac{477}{110} = 4.3$$

Figure 2 - Category Ranking of The International Brazilian Journal of Urology.

CATEGORY				
UROLOGY & NEPHROLOGY				
18/134				
JCR YEAR	JIF RANK	QUART ILE	JIF PERCENTILE	
2025	18/134	Q1	86.9	
2024	16/133	Q1	88.3	
2023	28/126	Q1	78.2	

The September-October number of International Brazilian Journal of Urology presents original contributions with a lot of interesting papers in different fields: Prostate cancer, Robotic Surgery, Kidney cancer, Testicular cancer, Infertility, Erectile dysfunction and Reconstructive Urology. The papers came from many different countries such as Brazil, China, France and India, and as usual the editor's comment highlights some of them. The editor in chief would like to highlight the work about robotic surgery in kidney cancer

Dr. Pal and colleagues from India, presented in page xxxx (1) a nice study about the Suture versus Sutureless Retroperitoneal Robot- assisted Partial Nephrectomy (RAPN) using Veriset™ Hemostatic Patch and concluded that Veriset™ hemostatic patch during retroperitoneal RAPN can be considered as a safe and feasible alternative to conventional cortical renorrhaphy to achieve hemostasis and the trifecta outcome. It can bring down warm ischemia time, console time, and blood loss without increasing the complications and reducing the renal function. However, as the study population predominantly comprised low nephrometry score tumors, the role of this approach in moderate- and high-complexity renal masses remains to be established and warrants validation in larger studies.

Robotic surgery has revolutionized the urologic surgery, resulting in better outcomes and faster recovery (2-9). The present study is interesting and will greatly assist the urologist in treatment of kidney cancer.

The Editor-in-chief expects everyone to enjoy reading.

CONFLICT OF INTEREST

None declared.

REFERENCES

1. Liang H, Xu Y, Peng Y, Huang T, Zheng Q, Yang X, et al. Tubeless Retroperitoneal Robot-assisted Partial Nephrectomy: An Innovative Approach to Treat Early Renal Tumor. *Int Braz J Urol.* 2026 Jul-Aug;52(4). pii: e20260042. doi: 10.1590/S1677-5538.IBJU.2026.0042.
2. Moschovas MC, Jaber A, Saikali S, Sandri M, Bhat S, Rogers T, et al. Impacts on functional and oncological outcomes of robotic-assisted radical prostatectomy 10 years after the US Preventive Service Taskforce recommendations against PSA screening. *Int Braz J Urol.* 2024;50(1):65-79. doi: 10.1590/S1677-5538.IBJU.2023.0530
3. Jiao RD, Wang Z, Kong XG, Tang SY, Xia D, Wu ZJ, et al. Clinical outcomes and cost-effectiveness between the Sentire® and da Vinci® systems in robot-assisted radical prostatectomy. *Int Braz J Urol.* 2025;51(4):e20240706. doi: 10.1590/S1677-5538.IBJU.2024.0706
4. Gamal A, Moschovas MC, Saikali S, Reddy S, Ozawa Y, Sharma R, et al. Comparing the technological and intraoperative performances of Da Vinci Xi and Da Vinci 5 robotic platforms in patients undergoing robotic-assisted radical prostatectomy. *Int Braz J Urol.* 2025;51(1):e20240569. doi: 10.1590/S1677-5538.IBJU.2024.0569
5. Pires RDS, Pereira CWA, Favorito LA. Is the learning curve of the urology resident for conventional radical prostatectomy similar to that of staff initiating robot-assisted radical prostatectomy? *Int Braz J Urol.* 2024;50(3):335-45. doi: 10.1590/S1677-5538.IBJU.2024.9909
6. Sakthivel DK, Prabhakar P, Raja MJ, et al. Maximal anatomic bladder neck preservation at the prostatic origin (MANO) in robotic radical prostatectomy: does prostate size matter? *J Robot Surg.* 2025;19(1):707. doi: 10.1007/s11701-025-02880-7
7. Zhang Z, Li Z, Xu W, Wang X, Zhu S, Dong J, et al. Robot-assisted radical nephroureterectomy using the KangDuo Surgical Robot-01 System versus the da Vinci System: a multicenter prospective randomized controlled trial. *Int Braz J Urol.* 2024;50(6):727-36. doi: 10.1590/S1677-5538.IBJU.2024.0230

8. Orsini A, Lasorsa F, Bignante G, Yoon J, Dymanus KA, Cherullo EE, et al. Single port robotic nephrectomy via lower anterior retroperitoneal approach: feasible, safe and effective option in surgically complex patients. *Int Braz J Urol.* 2024;50(6):785-6. doi: 10.1590/S1677-5538.IBJU.2024.0420
9. Silvestri A, Gavi F, Sighinolfi MC, Assumma S, Panio E, Fettucciari D, et al. Management of small renal masses: literature and guidelines review. *Int Braz J Urol.* 2025;51(5):e20250203. doi: 10.1590/S1677-5538.IBJU.2025.0203

Luciano A. Favorito, MD, PhD

Unidade de Pesquisa Urogenital
da Universidade do Estado de Rio de Janeiro - UERJ,
Rio de Janeiro, RJ, Brasil
E-mail: lufavorito@yahoo.com.br

ARTICLE INFO

 **Luciano A. Favorito**
<https://orcid.org/0000-0003-1562-6068>